Macquarie Upgrades Core Scientific, Inc.

Macquarie upgraded Core Scientific (OTCPK:CORZR) to Outperform on October 31, 2025, despite an average one-year analyst price target of $0.06/share, which implies a significant 79.95% downside from its latest closing price of $0.32. This conflicting outlook is underscored by a 33.67% decrease in total institutional shares owned over the last three months, including BlackRock Credit Strategies Fund reducing its position by over 50%, even as the company projects an 83.63% increase in annual revenue to $614 million.

Analysis

Macquarie's upgrade of Core Scientific (OTCPK:CORZR) to Outperform on October 31, 2025, presents a notable divergence from the broader analyst consensus. The average one-year price target for CORZR stands at $0.06/share, implying a substantial 79.95% downside from its recent closing price of $0.32, with forecasts ranging from $0.05 to $0.09. This stark contrast between an upgrade and a deeply negative price target signals significant uncertainty regarding the equity's future valuation.

Despite a projected annual revenue increase of 83.63% to $614 million, the company anticipates a non-GAAP EPS of -0.01, indicating continued unprofitability. Institutional investor sentiment appears bearish, with total shares owned by institutions decreasing by 33.67% to 328K shares over the last three months. Notably, BlackRock Credit Strategies Fund reduced its position by 50.76% and its portfolio allocation in CORZR by 86.80%.

The overall market sentiment for CORZR is extremely negative, with a bearish tone, despite Macquarie's positive re-rating. This suggests that the significant implied downside from consensus price targets and the substantial institutional selling are outweighing the projected revenue growth and the single analyst upgrade. Investors should carefully consider this pronounced disconnect and the underlying fundamental challenges.

Key Decisions for Investors

• Investors should exercise extreme caution given the significant 79.95% implied downside from the average analyst price target, despite Macquarie's recent upgrade to Outperform
• Closely monitor institutional ownership trends, especially the continued selling by major funds like BlackRock, as this indicates a lack of conviction
• Evaluate the sustainability of projected revenue growth against the backdrop of persistent unprofitability, as indicated by the negative non-GAAP EPS forecast